MX2021000472A - Inhibidores de trombina, formulaciones y usos de estos. - Google Patents
Inhibidores de trombina, formulaciones y usos de estos.Info
- Publication number
- MX2021000472A MX2021000472A MX2021000472A MX2021000472A MX2021000472A MX 2021000472 A MX2021000472 A MX 2021000472A MX 2021000472 A MX2021000472 A MX 2021000472A MX 2021000472 A MX2021000472 A MX 2021000472A MX 2021000472 A MX2021000472 A MX 2021000472A
- Authority
- MX
- Mexico
- Prior art keywords
- formulations
- thrombin
- thrombin inhibitors
- compounds
- pyrazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862697817P | 2018-07-13 | 2018-07-13 | |
| PCT/US2019/041699 WO2020014669A1 (en) | 2018-07-13 | 2019-07-12 | Thrombin inhibitors, formulations, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000472A true MX2021000472A (es) | 2021-06-23 |
Family
ID=67470750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000472A MX2021000472A (es) | 2018-07-13 | 2019-07-12 | Inhibidores de trombina, formulaciones y usos de estos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11865110B2 (enExample) |
| EP (1) | EP3820564A1 (enExample) |
| JP (2) | JP2021531338A (enExample) |
| KR (1) | KR20210080347A (enExample) |
| CN (1) | CN113164765B (enExample) |
| AU (1) | AU2019300161B2 (enExample) |
| BR (1) | BR112021000515A2 (enExample) |
| CA (1) | CA3106359A1 (enExample) |
| IL (1) | IL280078B2 (enExample) |
| MX (1) | MX2021000472A (enExample) |
| SG (1) | SG11202100247WA (enExample) |
| WO (1) | WO2020014669A1 (enExample) |
| ZA (1) | ZA202100955B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116735514B (zh) * | 2023-08-11 | 2023-11-03 | 昆明理工大学 | 纳米酶结合液液微萃取快速检测天麻硫熏标志物的方法 |
| WO2025184627A1 (en) * | 2024-03-01 | 2025-09-04 | Cadrenal Therapeutics, Inc. | Method for preventing coagulation in patients with implanted cardiac devices |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5579843A (en) | 1994-08-16 | 1996-12-03 | Loitherstein; Joel S. | Resilient spider for well installation |
| SE9900070D0 (sv) | 1999-01-13 | 1999-01-13 | Astra Ab | New use |
| SI21097A (sl) | 2001-12-04 | 2003-06-30 | Univerza V Ljubljani | Inhibitorji trombina |
| SE0200198D0 (sv) | 2002-01-23 | 2002-01-23 | Astrazeneca Ab | New use |
| AR061996A1 (es) | 2006-07-17 | 2008-08-10 | Boehringer Ingelheim Int | Indicaciones para los inhibidores directos de la trombina en el campo cardiovascular |
| EA201100358A1 (ru) | 2008-08-19 | 2011-10-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Дабигатран для чрескожной хирургической катетеризации сердца |
| US20110190352A1 (en) | 2008-08-19 | 2011-08-04 | Boehringer Ingelheim International Gmbh | Use of dabigatranetexilate for treating patients with pulmonary hypertension |
| WO2010020601A1 (en) | 2008-08-19 | 2010-02-25 | Boehringer Ingelheim International Gmbh | Dabigatran in tumour therapy |
| WO2014145986A1 (en) * | 2013-03-15 | 2014-09-18 | Verseon, Inc. | Multisubstituted aromatic compounds as serine protease inhibitors |
| KR20170048410A (ko) * | 2014-09-17 | 2017-05-08 | 베르선 코포레이션 | 세린 프로테아제 저해제로서의 피라졸릴-치환된 피리돈 화합물 |
-
2019
- 2019-07-12 IL IL280078A patent/IL280078B2/en unknown
- 2019-07-12 MX MX2021000472A patent/MX2021000472A/es unknown
- 2019-07-12 CN CN201980059868.XA patent/CN113164765B/zh active Active
- 2019-07-12 EP EP19745941.5A patent/EP3820564A1/en active Pending
- 2019-07-12 KR KR1020217004016A patent/KR20210080347A/ko not_active Ceased
- 2019-07-12 AU AU2019300161A patent/AU2019300161B2/en active Active
- 2019-07-12 WO PCT/US2019/041699 patent/WO2020014669A1/en not_active Ceased
- 2019-07-12 CA CA3106359A patent/CA3106359A1/en active Pending
- 2019-07-12 BR BR112021000515-3A patent/BR112021000515A2/pt unknown
- 2019-07-12 US US17/259,108 patent/US11865110B2/en active Active
- 2019-07-12 SG SG11202100247WA patent/SG11202100247WA/en unknown
- 2019-07-12 JP JP2021523581A patent/JP2021531338A/ja active Pending
-
2021
- 2021-02-11 ZA ZA2021/00955A patent/ZA202100955B/en unknown
-
2025
- 2025-02-28 JP JP2025031155A patent/JP2025098029A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3106359A1 (en) | 2020-01-16 |
| JP2025098029A (ja) | 2025-07-01 |
| US20210315877A1 (en) | 2021-10-14 |
| CN113164765B (zh) | 2026-03-20 |
| US11865110B2 (en) | 2024-01-09 |
| JP2021531338A (ja) | 2021-11-18 |
| AU2019300161B2 (en) | 2025-05-22 |
| IL280078B1 (en) | 2023-12-01 |
| IL280078A (en) | 2021-03-01 |
| WO2020014669A1 (en) | 2020-01-16 |
| BR112021000515A2 (pt) | 2021-04-06 |
| KR20210080347A (ko) | 2021-06-30 |
| AU2019300161A1 (en) | 2021-02-25 |
| EP3820564A1 (en) | 2021-05-19 |
| CN113164765A (zh) | 2021-07-23 |
| ZA202100955B (en) | 2023-10-25 |
| IL280078B2 (en) | 2024-04-01 |
| SG11202100247WA (en) | 2021-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY209609A (en) | Immunomodulators, compositions and methods thereof | |
| NZ775660A (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| MX2021004431A (es) | Procesos novedosos. | |
| MY210070A (en) | Heterocyclic compounds as immunomodulators | |
| EA202091491A1 (ru) | Новые бензиламинозамещенные пиридопиримидиноны и производные в качестве ингибиторов sos1 | |
| PH12018501920B1 (en) | Bromodomain inhibitors | |
| PH12020552154A1 (en) | Compounds | |
| ZA202204941B (en) | Cd73 inhibitors | |
| EP4464317A3 (en) | Compounds and compositions and uses thereof | |
| MY174747A (en) | Bace1 inhibitors | |
| EA202191955A1 (ru) | Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы | |
| MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. | |
| PH12022551623A1 (en) | Substituted pyrazolo-pyrimidines and uses thereof | |
| EA202191548A1 (ru) | Ингибиторы плазменного калликреина человека | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| WO2018183631A8 (en) | Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same | |
| MX2021013602A (es) | Inhibidores de jak. | |
| PH12019501642A1 (en) | Novel compounds and their use in the treatment of schistosomiasis | |
| TN2018000214A1 (en) | Alkyl dihydroquinoline sulfonamide compounds | |
| ZA202100955B (en) | Thrombin inhibitors, formulations, and uses thereof | |
| PH12021550258A1 (en) | Cdk8/19 inhibitors | |
| PH12021550143A1 (en) | Pyridopyrimidines as histamine h4-receptor inhibitors | |
| PH12021550093A1 (en) | Compounds for use in the treatment of fascioliasis | |
| PH12017501668A1 (en) | Bace1 inhibitors | |
| MX2022016357A (es) | Derivados de tetrazol como inhibidores de trpa1. |